Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - A randomised study

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 3, 2013, Pages 303-312

  Pocha, C ^a,b   Dieperink, E ^a,b   McMaken, K A ^a   Knott, A ^a,b   Thuras, P ^a,b   Ho, S B ^c,d  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINGENCY TABLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; HEPATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CANCER; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SURVIVAL; VETERAN;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; UNITED STATES;

EID: 84879728484     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12370     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Kew MC,. Hepatocellular cancer. A century of progress. Clin Liver Dis 2000; 4: 257-68.
3. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
4. Bruix J, Sherman M, Llovet JM, et al,. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
5. Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB,. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 989-94.
6. Andersson KL, Salomon JA, Goldie SJ, Chung RT,. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008; 6: 1418-24.
7. Trinchet JC, Chaffaut C, Bourcier V, et al,. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-97.
8. Trevisani F, De Notariis S, Rapaccini G, et al,. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-44.
9. Colli A, Fraquelli M, Casazza G, et al,. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-23.
10. Altekruse SF, McGlynn KA, Reichman ME,. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
11. Center for Disease Control and Prevention. Hepatocellular carcinoma-United States 2001-2006. MMWR Morb Mortal Wkly Rep 2010; 59: 517-20.
12. Davila JA, Henderson L, Kramer JR, et al,. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected Veterans in the United States. Ann Intern Med 2011; 154: 85-93.
13. Dominitz JA, Boyko EJ, Koepsell TD, et al,. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005; 41: 88-96.
14. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA,. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516 e1.
15. Phibbs CS, Bhandari A, Yu W, Barnett PG,. Estimating the costs of VA ambulatory care. Med Care Res Rev 2003; 60 (Suppl. 3): 54S-73S.
16. HERC. B6. How do VA costs compare to the cost of non-VA providers? Available at: http://www.herc.research.va.gov/resources/faq-b06.asp. Accessed March 7, 2013.
17. HERC. B7. Comparison of VA and Medicare costs. Available at: http://www.herc.research.va.gov/resources/faq-b07.asp. Accessed March 7, 2013.
18. Ren FY, Piao XX, Jin AL,. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 4656-9.
19. Llovet JM, Fuster J, Bruix J,. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
20. Zhang BH, Yang BH, Tang ZY,. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
21. Chen JG, Parkin DM, Chen QG, et al,. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-9.
22. Colombo M, de Franchis R, Del Ninno E, et al,. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
23. Fasani P, Sangiovanni A, De Fazio C, et al,. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704-7.
24. Pateron D, Ganne N, Trinchet JC, et al,. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
25. McMahon BJ, Bulkow L, Harpster A, et al,. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-6.
26. Farinati F, Gianni S,. Surveillance for hepatocellular carcinoma in cirrhosis: is it cost-effective? Eur J Cancer Prev 2001; 10: 111-5.
27. Caturelli E, Bartolucci F, Biasini E, et al,. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397-405.
28. Stravitz RT, Heuman DM, Chand N, et al,. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008; 121: 119-26.
29. Singal A, Volk ML, Waljee A, et al,. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
30. Berrington de Gonzalez A, Mahesh M, Kim KP, et al,. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 2009; 169: 2071-7.
31. Snowberger N, Chinnakotla S, Lepe RM, et al,. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007; 26: 1187-94.
32. Seitz K, Bernatik T, Strobel D, et al,. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI-a prospective comparison in 269 patients. Ultraschall Med 2010; 31: 492-9.
33. Singal AG, Conjeevaram HS, Volk ML, et al,. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-9.
34. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T,. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 368-70.